Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

MEDI vs DNA: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

MEDI Captures Overall Composite Edge (42.1 HOLD vs 57.4 HOLD), While DNA Leads 3–2 on Growth & Valuation Pillars

MEDI Overall Winner 6-Pillar Tally: MEDI 2 – 3 DNA (1 Tie) Matrix Metrics: MEDI 2 – 6 DNA

As of Nov 16, 2026, Harbor Health Care ETF (MEDI) captures the overall head-to-head institutional edge over Ginkgo Bioworks Holdings, Inc. (DNA) on higher Unified Composite conviction (42.1/100 HOLD vs. 57.4/100 HOLD) after splitting the core matrix 2–6 (led by Balance Sheet & Cash Flow, Options & Positioning), while DNA wins 3–2 across the 6-pillar growth and valuation breakdown. MEDI trades at $35.59 (N/M Forward P/E, N/A operating margin) versus DNA at $8.50 (N/M Forward P/E, -202.5% operating margin).

  • Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (57.4/100 HOLD vs. MEDI 42.1/100 HOLD), MEDI captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. -202.5% operating margin) and revenue trajectory (N/A vs. -5.7% YoY).
  • Technical & Structure Timing Caution: MEDI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.4); meanwhile DNA is in a Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About MEDI vs DNA
MEDI NYSE Arca Head-to-Head Winner
Harbor Health Care ETF
Institutional Equity
$35.59
-2.05% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.59β · 22% Vol
Unified Composite Score
42.1 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 22.2
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (0.5% over 20 days), RSI 58
RSI-14: 58.4 · SMA20: $34.95 · SMA50: $33.68
DNA NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap $623.0M
TTM Revenue $131M
Forward P/E N/M
Beta / 30D Vol 3.14β · 152% Vol
Unified Composite Score
57.4 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 68.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 41
RSI-14: 40.7 · SMA20: $10.73 · SMA50: $10.32

6-Pillar Scorecard Institutional Category Breakdown (MEDI 2 – 3 DNA)

Columns: Metric · MEDI · DNA
1. Valuation Multiples DNA
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M 7.2x
2. Growth & Scale DNA
Revenue Growth (YoY) N/A -5.7%
Earnings Growth (YoY) N/A +0.0%
TTM Revenue (USD) N/A $131M
Market Cap N/A $623.0M
3. Profitability & Quality DNA
Gross Margin N/A 69.8%
Operating Margin N/A -202.5%
Net Profit Margin N/A -192.0%
Return on Equity (ROE) N/A -58.2%
4. Balance Sheet & Cash Flow MEDI
Cash Generation (TTM) N/A -$174M
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE $313M Net Debt (1.01x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning MEDI
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 119.2% (34th %ile)
Put/Call OI Skew N/A 0.13x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: MEDI (2) vs DNA (6)
Institutional Metric MEDI DNA Criterion Row Edge
Market Capitalization
Scale
N/A $623.0M Larger Scale DNA
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A -5.7% Higher Growth DNA
Operating Margin (TTM)
Profitability
N/A -202.5% Higher Margin DNA
Net Profit Margin
Profitability
N/A -192.0% Higher Margin DNA
Return on Equity (ROE)
Capital Efficiency
N/A -58.2% Higher ROE DNA
52-Week Range Position
Momentum
90% ($28–$37) 24% ($5–$18) Stronger Trend MEDI
Beta / 30D Volatility
Risk Regime
0.59β · 22% Vol 3.14β · 152% Vol Lower Realized Risk MEDI
Unified Institutional Score
Composite Signal
42.1 / 100 (HOLD) 57.4 / 100 (HOLD) Higher Composite DNA
Trailing 12M Revenue (USD)
Operating Scale
N/A $131M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A 69.8% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · 7.2x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) -$174M ($313M Net Debt (1.01x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon MEDI +27.15 pp
MEDI: +9.92% · DNA: -17.23%
3M Horizon DNA +27.01 pp
MEDI: +3.16% · DNA: +30.17%
6M Horizon MEDI +4.46 pp
MEDI: +19.79% · DNA: +15.33%
1Y Horizon MEDI +8.43 pp
MEDI: +14.68% · DNA: +6.25%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MEDI vs DNA. Trailing 12-month operating profitability (MEDI N/A vs DNA -202.5%) and valuation multiples (MEDI N/M vs DNA N/M Forward P/E) are benchmarked directly in Pillar 4 below.

MEDI ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
DNA ADR TTM Benchmark FX-Normalized USD
TTM Revenue$131M
Gross Margin69.8%
Op. Margin-202.5%
ROE / Fwd P/E-58.2% · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
MEDI UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact MEDI Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
DNA BREAKDOWN
30d in phase · OBV DISTRIBUTION
Current IV 119.2%
IV Percentile 34th %ile
Put/Call OI Skew 0.13x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact DNA Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
MEDI Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
DNA Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $623.0M market capitalization and -202.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ MEDI vs DNA Key Questions & Quantitative Answers

As of Nov 16, 2026, Harbor Health Care ETF (MEDI) captures the overall head-to-head institutional edge over Ginkgo Bioworks Holdings, Inc. (DNA) on higher Unified Composite conviction (42.1/100 HOLD vs. 57.4/100 HOLD) after splitting the core matrix 2–6 (led by Balance Sheet & Cash Flow, Options & Positioning), while DNA wins 3–2 across the 6-pillar growth and valuation breakdown. MEDI trades at $35.59 (N/M Forward P/E, N/A operating margin) versus DNA at $8.50 (N/M Forward P/E, -202.5% operating margin). Composite vs. Pillar Nuance: While DNA currently prints a higher short-term Unified Composite Score (57.4/100 HOLD vs. MEDI 42.1/100 HOLD), MEDI captures the overall institutional head-to-head verdict (2–6 matrix metrics and 2–3 across the 6 pillars) due to superior fundamental profitability (N/A vs. -202.5% operating margin) and revenue trajectory (N/A vs. -5.7% YoY). Technical & Structure Timing Caution: MEDI trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 58.4); meanwhile DNA is in a Breakdown options structure phase (RSI 40.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

DNA leads the Growth & Scale pillar: MEDI posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with DNA at -5.7% YoY revenue growth and +0.0% YoY earnings growth on $131M TTM revenue (69.8% gross margin, -202.5% operating margin). On trailing 12-month operating scale, MEDI generates N/A in USD-normalized revenue versus $131M for DNA. In operating R&D and SG&A reinvestment, MEDI deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for DNA.

DNA screens cheaper on headline valuation multiples. MEDI trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas DNA trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 7.2x EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against MEDI (N/A ROE) versus DNA (-58.2% ROE) capital efficiency.

In options market volatility and institutional positioning, MEDI carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.59β · 22% Vol realized risk). By comparison, DNA carries 119.2% implied volatility (34th %ile, Balanced (25th–60th %ile)), a 0.13x (Call-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (3.14β · 152% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.